A comparative study of breast cell proliferation during hormone replacement therapy: Effects of tibolone and continuous combined estrogen-progestogen treatment

Climacteric

Volumn 7, Issue 1, 2004, Pages 50-58

  Conner, P ^a   Christow, A ^a   Kersemaekers, W ^b   Soderqvist G ^a   Skoog, L ^a   Carlstrom K ^a   Tani, E ^a   Mol Arts, M ^b   Von Schoultz, B ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Clinical Development Department   (Netherlands)

Author keywords

Breast cell proliferation; Fine needle aspiration cytology; Hormone replacement therapy; Tibolone

Indexed keywords

ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN DERIVATIVE; MONOCLONAL ANTIBODY KI 67; PLACEBO; PROGESTERONE DERIVATIVE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TESTOSTERONE; TIBOLONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASPIRATION BIOPSY; ASSOCIATION; BODY MASS; BREAST CELL; CELL PROLIFERATION; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EVALUATION; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL RECORD; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL;

AGED; ANTIBODIES, MONOCLONAL; BIOPSY, NEEDLE; BREAST; CELL DIVISION; CONTRACEPTIVES, ORAL, SYNTHETIC; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NORETHINDRONE; NORPREGNENES; PROSPECTIVE STUDIES;

EID: 1642401373     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/13697130310001651472     Document Type: Article

References (29)

1. Barrett-Connor E. Hormone replacement therapy. Br Med J 1998;317:457-61
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33
3. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362: 419-27
4. Preston-Martin S, Pike MC, Ross RK, et al. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415-21
5. Santen RJ, Pinkerton J, McCartney C, et al. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 2001;86:16-23
6. Moore RA. Livial: a review of clinical studies. Br J Obstet Gynaecol 1999;106:1-21
7. Rymer JM. The effects of tibolone. Gynecol Endocrinol 1998;12:213-20
8. Pasqualini JR, Chetrite GS. Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications. J Steroid Biochem Mol Biol 1999;69:287-92
9. Gompel A, Chaouat M, Jacob D, et al. In vitro studies of tibolone in breast cells. Fertil Steril 2002;78:351-9
10. Hofseth LJ, Raafat AM, Osuch JR, et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-65
11. Franzén S, Zajicek J. Aspiration biopsy in diagnosis of palpable lesions of the breast. Critical review of 3479 consecutive biopsies. Acta Radiol Ther Phys Biol 1968;7:241-62
12. Skoog L, Humla S, Isaksson S, et al. Immunocytochemical analysis of receptors for estrogen and progesterone in fine-needle aspirates from human breast carcinomas. Diagn Cytopathol 1990;6:95-8
13. Skoog L, Rutqvist LE, Wilking N. Analysis of hormone receptors and proliferation fraction in fine-needle aspirates from primary breast carcinomas during chemotherapy or tamoxifen treatment. Acta Oncol 1992;31:139-41
14. Söderqvist G, Isaksson E, von Schoultz B, et al. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 1997;176:123-8
15. Isaksson E, von Schoultz E, Odlind V, et al. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 2001; 65:163-9
16. Conner P, Skoog L, Söderqvist G. Breast epithelial proliferation in postmenopausal women evaluated through fine-needle-aspiration cytology. Climacteric 2001;4:7-12
17. Conner P, Söderqvist G, Skoog L, et al. Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology. Breast Cancer Res Treat 2003;78: 159-65
18. Lundström E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717-22
19. Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867-73
20. Södergård R, Bäckström T, Shanbhag V, et al. Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature. J Steroid Biochem 1982;187:801-10
21. Reid SE, Murthy MS, Kaufman M, et al. Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br J Surg 1996;83:1037-46
22. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347:1713-27
23. Boyd NF, Lockwood GA, Byng JW, et al. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomark Prev 1998; 7:1133-44
24. Lundström E, Wilczek B, von Palffy Z, et al. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 1999;81: 348-52
25. Kloosterboer HJ, Schoonen WG, Deckers GH, et al. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. J Steroid Biochem Mol Biol 1994;49:311-18
26. Zhou J, Ng S, Adesanya-Famuiya O, et al. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 2000; 12:1725-30
27. Pye JK, Mansel RE, Hughes LE. Clinical experience of drug treatments for mastalgia. Lancet 1985;2:373-7
28. Dimitrakakis O, Zhou J, Wang J, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003; 10:292-8
29. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-9